Market evolution: Corticosteroid drugs (CN 300432) — 2015–2025

Introduction

This report analyses the trade evolution of medicaments containing corticosteroid hormones (CN 300432) by the European Union with non-EU countries between 2015 and 2025. The period has been characterized by significant growth in export values, a major reorientation of import sources, and increased price volatility, culminating in a strengthening of the EU's overall trade balance and strategic positioning. The analysis is based on the provided trade data, focusing on value, quantity, and unit price trends, as well as the dynamics with key trading partners.

Sustained Export Expansion and Import Price Surge

Over the decade, the EU consolidated its position as a major global exporter of corticosteroid drugs. While import values also rose sharply, the growth trajectory was markedly different, driven by volatile quantities and a dramatic increase in import prices, especially post-2020.

Export Value Growth Outpaced by Volume Increase

The EU's trade overview shows that export value grew from €4.05 billion in 2015 to €4.61 billion in 2025, a 13.8% increase. However, the quantity exported grew by 29.6%, from 20,466 to 26,526 tonnes. This divergence indicates a 12.2% decline in the average export price (from ~€198,000/t to ~€174,000/t), suggesting competitive pricing or a shift in the product mix towards lower-value items.

Import Value Driven by Price Volatility, Not Volume

In contrast, the value of imports more than doubled, soaring by 110.7% to €783 million in 2025. This was not a volume-driven story; imported quantities actually fell by 15.1% over the period. The primary driver was a 148.3% explosion in the average import price, which climbed from ~€84,000/t in 2015 to ~€209,000/t in 2025. This extreme price inflation, particularly evident between 2020 and 2022, reflects significant supply chain stress and possibly changes in the composition of imported goods.

Resilient Trade Balance and a Strong Net Exporter Position

Despite the surge in import costs, the EU maintained a robust and growing trade surplus. The balance in value terms increased from €3.68 billion to €3.83 billion (+4.0%). The EU's status as a net exporter is confirmed by a persistently negative net import reliance percentage. While the reported figure shows a dramatic worsening, this is a mathematical artifact of the formula applied to a large negative number, underscoring the bloc's dominant export orientation.

Geographic Reconfiguration and Extreme Price Shocks

The trade landscape saw significant geographic shifts, with new partners gaining prominence in imports and established partners facing challenges. This period was also marked by isolated but severe price shocks in the import supply chain.

Diversification of Import Sources, Led by the UK and India

Analysis of the top import partners reveals a major reconfiguration. While the United Kingdom remained the largest supplier (€503 million), its share of imports fell. The most dynamic growth came from India (+1,866.3% to €84 million) and Switzerland (+465.7% to €81 million). Meanwhile, traditional suppliers like the United States saw their import value fall by 28.2%.

Export Destinations: Growth in Asia, Decline in Traditional Markets

EU export flows pivoted towards Asia. Exports to China grew spectacularly by 163.9% to €604 million, making it the second-largest destination by 2025. In contrast, exports to Japan (-62.1%) and the United States (-31.7%) contracted significantly. Russia (+121.6%) also emerged as a major growth market.

The 2021 Price Shock in Imports

The volatility data pinpoints 2021 as a year of acute disruption in the import market. Two major supply shocks were detected:

1. United Kingdom imports: A price shock with an abnormality score of 49.6, where the unit price surged by 534% compared to the expected trend, accounting for 81.4% of import value that year.
2. Switzerland imports: An even more extreme price shock (abnormality 352.6), with a 209.7% price shift, constituting 11.4% of import value.

These shocks explain the historical peak in import prices and highlight the concentration risk in the EU's pharmaceutical supply chain during the post-COVID period.

Strengthening Industrial Base and Reduced Strategic Vulnerability

The final decade trend shows the EU's pharmaceutical industry expanding production capacity for this product category, thereby enhancing its trade autonomy and reducing dependency on external suppliers.

Rapid Growth in Domestic Production Value

Production value for corticosteroid medicaments within the EU grew by 164.2% over the period, from €6.38 billion to €16.86 billion. This growth significantly outpaced trade value increases, indicating that a larger share of the market is being supplied by EU-based manufacturers.

Declining Import Concentration Reflects Strategic Diversification

The Herfindahl-Hirschman Index (HHI) for import concentration by value remained high but showed minimal change (+0.4%). However, the HHI for import volume fell by 57.8%, from 5,285 to 2,232. This indicates that while the value remains dominated by a few key partners (likely the UK), the physical quantities are being sourced from a much broader and more diversified set of suppliers, enhancing supply chain resilience.

Ireland and Sweden as Specialised Export Hubs

Within the EU, production is highly concentrated in a few member states. For 2025, specialisation indices identify Ireland (RSCA: 0.71) and Sweden (RSCA: 0.52) as having a strong comparative advantage in exporting these products. Ireland's export value grew by 313.5% during the period, confirming its role as a major EU production and export hub for pharmaceuticals.

Conclusion

The 2015-2025 period has solidified the EU's role as a global leader in the corticosteroid drug market. The bloc successfully expanded its export volumes into growing Asian markets, most notably China, while managing a dramatic reorientation and inflation of its import sources. Despite facing severe price shocks in 2021, particularly from the UK and Switzerland, the underlying trend is one of reduced strategic vulnerability. This is evidenced by the massive growth in EU domestic production value and the diversification of import supply volumes. The overall trade balance remains strongly positive, and the industrial base is strengthening, positioning the EU for continued resilience and competitiveness in this critical pharmaceutical sector.